PharmAla will seek to finalize the license and data sharing agreement prior to the conclusion of the 2024 calendar year. The identity of the trial Principal Investigators and institution is currently ...

Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, ...

Research and development expenses were $11.4 million for the third quarter ended September 30, 2024, compared to $11.7 million for the comparable period in 2023. The decrease was primarily related to ...

NorthStar to provide Cellectar with non-carrier-added Ac-225 for its expanded portfolio of clinical programsFLORHAM PARK, N.J., Nov. 14, 2024 ...

The decrease was primarily related to lower costs with contract manufacturing organizations for the production of pre-clinical and future clinical trial supply. General and administrative expenses ...

Existing supply chains for medical radioisotopes are often strained ... patient enrollment and the completion of clinical studies, the FDA review process and other government regulation, our ability ...

Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage biopharmaceutical company focused on harnessing the power of trained immunity for the prevention and ...

Bloodletting therapy at well points is thought to promote microcirculation and peripheral blood flow, effectively redirecting the body’s heat outward and enhancing the brain’s oxygen supply ... with a ...

Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and ...

The Master Services Agreement (MSA) and Clinical Supply Agreement with Nucleus RadioPharma complement the existing agreement with NorthStar Medical Radioisotopes, LLC (NorthStar) for 67Cu-SAR-bisPSMA ...

Canadian psychedelic stock PharmAla Biotech (CSE:MDMA) is up after signing a contract to supply MDMA for a clinical trial at Yale University ・The company is actively expanding its roster of research ...